GHRP 6 (5mg x 10 Vials) and Ipamorelin (5mg x 10 Vials)

GHRP-6 & Ipamorelin Peptide Combination

Research peptides / unlicensed medicinal products

Growth hormone\u2013releasing peptide combination (lyophilised vials)

No MHRA marketing authorisation identified for this peptide combination as a medicinal product in the UK.
No specific CE marking as a medical device is indicated for this research peptide bundle.
Marketed in the category of research chemicals/peptides, typically outside the scope of licensed medicines regulation when sold strictly for laboratory use.

No MHRA marketing authorisation identified for this peptide combination as a medicinal product in the UK.
No specific CE marking as a medical device is indicated for this research peptide bundle.
Marketed in the category of research chemicals/peptides, typically outside the scope of licensed medicines regulation when sold strictly for laboratory use.

Growth hormone\u2013releasing peptide combination (lyophilised vials)

Description

This product is a peptide bundle consisting of GHRP-6 and Ipamorelin supplied as lyophilised powders in separate vials. Each bundle contains 10 vials of GHRP-6 (5 mg per vial) and 10 vials of Ipamorelin (5 mg per vial). It is marketed as a research peptide combination and is typically labelled for laboratory or research use only, not for human or veterinary administration.

Bnefits

Provides two distinct growth hormone–releasing peptides (GHRP-6 and Ipamorelin) in a single bundle for experimental use.
Standard 5 mg per vial presentation for each peptide simplifies concentration calculations in research settings.
Ten vials of each peptide support repeated experiments or multi-sample protocols.
Lyophilised (freeze-dried) format helps maintain peptide stability during storage and shipping prior to reconstitution.
Intended for use in pre-clinical or in vitro research exploring growth hormone secretagogue pathways (not for clinical or human use).

Indications

Sold and labelled as research peptides for laboratory investigation only.
Not indicated as a licensed treatment for any human or veterinary medical condition.
Any clinical, performance-enhancement or aesthetic use would be outside authorised medicinal frameworks and may be unsafe or illegal.

Composition

GHRP-6 peptide (Growth Hormone Releasing Peptide-6) – 5 mg per lyophilised vial (10 vials in the bundle).
Ipamorelin peptide – 5 mg per lyophilised vial (10 vials in the bundle).
Lyophilised (freeze-dried) peptide powder in vials; any excipients (e.g. mannitol or buffering agents) are not specified in the public listing.

Formulation

Lyophilised peptide powders supplied in glass vials.
Each GHRP-6 vial contains 5 mg peptide in dry form.
Each Ipamorelin vial contains 5 mg peptide in dry form.
Intended to be reconstituted with a suitable sterile diluent in research environments according to institutional protocols (not for injection into humans or animals).

Packaging

10 x 5 mg vials of GHRP-6 lyophilised peptide.
10 x 5 mg vials of Ipamorelin lyophilised peptide.
Total of 20 vials supplied as a combination bundle.
Vials packed in protective outer packaging suitable for transport; detailed inner packaging configuration is not specified.
Typically labelled as research use only / not for human consumption.

Usage

Intended for laboratory research use only; not approved for human or veterinary administration.
Handling, reconstitution, storage and disposal must follow institutional guidelines for research chemicals and peptides.
Do not self-administer or use clinically; there is no validated dosing, safety or quality assurance for medicinal use in humans.
Researchers should consult institutional protocols and any supplier documentation for guidance on reconstitution volumes and handling.
Use appropriate personal protective equipment and aseptic technique when preparing and handling peptide solutions in a lab setting.

Contraindications

Not for human or veterinary use; self-administration or non-research use is contraindicated and potentially dangerous.
Should not be used as a substitute for licensed medicines or under unsupervised conditions.
Use outside controlled research environments is contraindicated in individuals with any medical condition or those taking other medications.
Not to be used by pregnant or breastfeeding individuals, minors or any non-research subjects.

Adverse Effects

No formal safety profile exists for this commercial product in humans, as it is sold for research use only.
Non-research use (e.g. self-injection) may pose serious, unpredictable risks such as endocrine disruption, cardiovascular strain, metabolic disturbances, local injection reactions or infection.
Products in the research peptide market may be mislabelled, contaminated or inaccurately dosed, further increasing risk if misused.

Storage Conditions

Store vials in a cool, dry place according to any temperature instructions on the packaging or labels.
Keep protected from direct light and moisture.
If recommended by the supplier, refrigerate or deep-freeze lyophilised peptides to preserve stability; follow any specific label guidance.
Keep out of reach of unauthorised personnel, children and pets.
Once reconstituted in a research setting, handle solutions using aseptic techniques and discard according to institutional chemical/biological waste policies.